Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTO adherence and toxicity modeling study in oral capecitabine
2008-004097-41Phase 4Active
- Sponsor
- Hospices Civils de Lyon
- Start
- Jul 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of capecitabine in breast cancer and colorectal cancer (CRC), sponsored by Hospices Civils de Lyon. Primary endpoints: Measurement of adherence and evaluation of the typical patient profile and Impact of adherence variation on toxicity markers. Started Jul 2008; status: active.
02
Drugs
capecitabine
03
Conditions
breast cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on 2008-004097-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004097-41.